Maybe I'm mistaken but doesn't 20 million x 100,000 = 2 trillion?
If correct, following your projection, it would yield a share price of $30.20 not $3020
Still not to shabby for one product and current share price of $4 - $5.
(Sorry to burst your bubble!).
Pfizer is not a stupid operation. They have to know that a successful relative "cure" for Dry AMD will significantly eliminate the need on a cure/treatment for Wet AMD.
You seem to mentally already have your Ocata stock "profits" in the bank but we are not there yet and I am trying to ascertain Pfizer's motive.
Pfizers program is on Wet AMD vs Ocata's on Dry AMD + Stargart's. Since Dry AMD is usually the predecessor to Wet AMD and with Ocata being a good 5+ years ahead of Pfizer, what is Pfizers real motive for running their program. They have to know that Ocata, if successful, will effectively supplant the commercial viability of a wet AMD treatment within a few years of Ocata RPE treatment going to market! So what could their "real" game plan be?
R U saying that Pfizer is paying Ocata a royalty or that Ocata is going to sue Pfizer for I.P. infringement?
What would happen (could happen) to the Incentive Rights (IR) and how might that negatively affect the distribution?
Touchy, touchy Mr BadDebt. Oh right it's all the fault of those Republicans.
Suggest you take your head out of the Asscandyandy!
See note #1: "
(1) Issued directly to Reporting Person by Issuer representing Board of Director Compensation.
Not an open market purchase. BOD COMPENSATION!
It is now clear to me that both you and Beareclawe are on this board with ulterior motives that are not in the best interest of the science and afflicted. You are correct that this is not an investment (yet) but neither was Microsoft not Apple until viable commercialization. The negatives that you and Bear continually bring up are in the past. This is no Genta. But whether it pays off or not will be determined within the next 12 to 24 months.
I think OCATA desperately needs a JV partner for both credibility and program expense participation. That no big pharma partner has been brought in is disturbing. IMO this is because either management is too greedy or think too highly of their own capabilities or potential JV partners are not convinced of the risk/return metrics, or the right JV is being worked on and will be formalized and announced within the next 3 months. All the more reason to understand that this is a speculation and not an investment.
Cam, until Ocat is on a definable path to commercialize it is a big speculation ( not an investment). Today the science is still not 100% defined and the science as a treatment has not been officially (FDA/EMA) sanctioned. Personally I believe in the science and in the probability for the success of commercialization, but the longer it takes to get there the lower the payback will be for those currently holding shares. if developments lead to a quicker path to commercialization you will regret not holding shares but otherwise you should only put at risk what you can comfortably afford to lose here. The best of luck to all Ocat longs and to the success of this company!
Read the transcript of the Wooten presentation (at Cantor seminar). All I can say is wow...........and also that the person in charge of OCAT publicity should be fired for no press release of successful share raise.
Is the lack of news of subscription sell-out (with over allotment) an indication of only a partial subscription? Is this info available to us peon shareholders?